Voltage-gated potassium channels as therapeutic targets

Wulff, H.; Castle, N. A.; Pardo, L. A.

doi:nrd2983 [pii]
10.1038/nrd2983

Datensatz

DATENSATZ AKTIONENEXPORT

Zur Ablage hinzufügen

Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben

Zeitschriftenartikel

Voltage-gated potassium channels as therapeutic targets

MPG-Autoren

Wulff, H.
Max Planck Society;

Castle, N. A.
Max Planck Society;

Pardo, L. A.
Max Planck Society;

Externe Ressourcen

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19949402
(beliebiger Volltext)

Volltexte (beschränkter Zugriff)

Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.

Volltexte (frei zugänglich)

Es sind keine frei zugänglichen Volltexte in PuRe verfügbar

Ergänzendes Material (frei zugänglich)

Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar

Zitation

Wulff, H., Castle, N. A., & Pardo, L. A. (2009). Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov, 8(12), 982-1001. doi:nrd2983 [pii] 10.1038/nrd2983.

Zitierlink: https://hdl.handle.net/21.11116/0000-0009-F22D-4

Zusammenfassung

The human genome encodes 40 voltage-gated K(+) channels (K(V)), which are involved in diverse physiological processes ranging from repolarization of neuronal and cardiac action potentials, to regulating Ca(2+) signalling and cell volume, to driving cellular proliferation and migration. K(V) channels offer tremendous opportunities for the development of new drugs to treat cancer, autoimmune diseases and metabolic, neurological and cardiovascular disorders. This Review discusses pharmacological strategies for targeting K(V) channels with venom peptides, antibodies and small molecules, and highlights recent progress in the preclinical and clinical development of drugs targeting the K(V)1 subfamily, the K(V)7 subfamily (also known as KCNQ), K(V)10.1 (also known as EAG1 and KCNH1) and K(V)11.1 (also known as HERG and KCNH2) channels.